Cognitive Effects of Immunomodulatory Drugs in MS

Completed

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).

Key facts

Study ID

NCT00229502

Run by

Sharon Lynch, MD

People needed

96

Starts

2005-09-01

Expected to finish

2011-12-01

Last updated by the study team

2012-03-23

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of RRMS for at least one year,
• Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif),
• Visual Acuity is 20/50 or better,
• patient has four color vision,
• Must have at least a high school education

You may not qualify if…

• History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current diagnosis of a severe or lifethreatening disease other than MS,
• currently taking immunosuppressant medication,
• resides greater than 200 miles from the study site

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.